# Innoviva, Inc.: overview

INVA · Nasdaq · CIK 1080014 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/inva.md) · [Financials](/companies/inva/financials.md) · [Filings](/companies/inva/filings.md) · [Insiders](/companies/inva/insiders.md)

Latest reported revenue: [$119.6m](/filings/0001193125-26-335235.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-335235).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [89.5](/filings/0001193125-25-267040.md) | [91.8 d](/filings/0001193125-26-071776.md) | [88.6](/filings/0001193125-26-209110.md) | [100](/filings/0001193125-26-335235.md) | [108](/filings/0001193125-25-267040.md) | [115 d](/filings/0001193125-26-071776.md) | [98.0](/filings/0001193125-26-209110.md) | [120](/filings/0001193125-26-335235.md) |
| Gross margin | % | [81.6%](/filings/0001193125-25-267040.md) | [85.1% d](/filings/0001193125-26-071776.md) | [82.7%](/filings/0001193125-26-209110.md) | [82.9%](/filings/0001193125-26-335235.md) | [70.1%](/filings/0001193125-25-267040.md) | [66.0% d](/filings/0001193125-26-071776.md) | [77.4%](/filings/0001193125-26-209110.md) | [75.8%](/filings/0001193125-26-335235.md) |
| Operating margin | % | [48.3%](/filings/0001193125-25-267040.md) | [47.0% d](/filings/0001193125-26-071776.md) | [46.7%](/filings/0001193125-26-209110.md) | [48.6%](/filings/0001193125-26-335235.md) | [32.1%](/filings/0001193125-25-267040.md) | [34.0% d](/filings/0001193125-26-071776.md) | [38.9%](/filings/0001193125-26-209110.md) | [42.5%](/filings/0001193125-26-335235.md) |
| Net margin | % | [1.4%](/filings/0001193125-25-267040.md) | [22.1% d](/filings/0001193125-26-071776.md) | [(52.6%)](/filings/0001193125-26-335235.md) | [63.5%](/filings/0001193125-26-335235.md) | [83.4%](/filings/0001193125-25-267040.md) | [143.2% d](/filings/0001193125-26-071776.md) | [190.4%](/filings/0001193125-26-335235.md) | [(69.8%)](/filings/0001193125-26-335235.md) |
| Diluted EPS | $ per share | [0.02](/filings/0001193125-25-267040.md) | not reported | [(0.74)](/filings/0001193125-26-209110.md) | [0.77](/filings/0001193125-26-335235.md) | [1.08](/filings/0001193125-25-267040.md) | not reported | [2.22](/filings/0001193125-26-209110.md) | [(1.14)](/filings/0001193125-26-335235.md) |
| Free cash flow | $m | [48.4 d](/filings/0001193125-25-267040.md) | [59.2 d](/filings/0001193125-26-071776.md) | [48.6](/filings/0001193125-26-209110.md) | [44.1 d](/filings/0001193125-26-335235.md) | [48.6 d](/filings/0001193125-25-267040.md) | [54.5 d](/filings/0001193125-26-071776.md) | [34.8](/filings/0001193125-26-209110.md) | [51.5 d](/filings/0001193125-26-335235.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [392](/filings/0000950170-24-025088.md) | [331](/filings/0000950170-25-027864.md) | [310](/filings/0001193125-26-071776.md) | [359](/filings/0001193125-26-071776.md) | [411](/filings/0001193125-26-071776.md) |
| Gross margin | % | not reported | not reported | [79.2%](/filings/0001193125-26-071776.md) | [82.6%](/filings/0001193125-26-071776.md) | [74.8%](/filings/0001193125-26-071776.md) |
| Operating margin | % | [95.7%](/filings/0000950170-22-004088.md) | not reported | [36.7%](/filings/0001193125-26-071776.md) | [46.5%](/filings/0001193125-26-071776.md) | [39.8%](/filings/0001193125-26-071776.md) |
| Net margin | % | [94.1%](/filings/0000950170-24-025088.md) | [66.5%](/filings/0000950170-25-027864.md) | [57.9%](/filings/0001193125-26-071776.md) | [6.5%](/filings/0001193125-26-071776.md) | [65.9%](/filings/0001193125-26-071776.md) |
| Diluted EPS | $ per share | [2.87](/filings/0000950170-24-025088.md) | [2.37](/filings/0000950170-25-027864.md) | [2.20](/filings/0001193125-26-071776.md) | [0.36](/filings/0001193125-26-071776.md) | [3.30](/filings/0001193125-26-071776.md) |
| Free cash flow | $m | [364](/filings/0000950170-24-025088.md) | [202](/filings/0000950170-25-027864.md) | [141](/filings/0001193125-26-071776.md) | [188](/filings/0001193125-26-071776.md) | [196](/filings/0001193125-26-071776.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Gross profit: us-gaap:GrossProfit.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/inva/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $262.4m | 11,555,209 |  | Added +247,364 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $102.1m | 4,494,053 |  | Added +57,626 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $95.8m | 4,220,273 |  | Reduced −4,678 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $91.7m | 4,036,532 |  | Reduced −19,100 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $74.2m | 3,268,004 |  | Added +207,627 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $71.7m | 3,158,053 |  | Added +16,472 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $57.7m | 2,541,109 |  | Added +261,658 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $47.1m | 2,074,709 |  | Added +144,991 |
| [SYSTEMATIC FINANCIAL MANAGEMENT LP](/funds/1085936.md) | 2026-06-30 | $46.0m | 2,023,565 |  | Reduced −517 |
| [Boston Partners](/funds/1386060.md) | 2026-06-30 | $43.8m | 1,927,959 |  | Added +209,092 |

## Recent filings

[All 1,334 filings](/companies/inva/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-05 | 16:26 ET | [10-Q](/filings/0001193125-26-335235.md) | Quarterly report, period 2026-06-30 | 0001193125-26-335235 |
| 2026-08-05 | 16:19 ET | [8-K](/filings/0001193125-26-335192.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-335192 |
| 2026-05-18 | 16:21 ET | [8-K](/filings/0001193125-26-228958.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-228958 |
| 2026-05-06 | 16:29 ET | [10-Q](/filings/0001193125-26-209110.md) | Quarterly report, period 2026-03-31 | 0001193125-26-209110 |
| 2026-05-06 | 16:19 ET | [8-K](/filings/0001193125-26-209044.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-209044 |
| 2026-05-04 | 16:59 ET | [8-K](/filings/0001193125-26-204243.md) | 5.07 Shareholder vote results | 0001193125-26-204243 |
| 2026-03-27 | 16:01 ET | [10-K/A](/filings/0001193125-26-128939.md) | Annual report, amended, period 2025-12-31 | 0001193125-26-128939 |
| 2026-03-24 | 16:51 ET | [DEF 14A](/filings/0001140361-26-010912.md) | Proxy statement, period 2026-03-24 | 0001140361-26-010912 |
| 2026-02-25 | 16:57 ET | [8-K](/filings/0001193125-26-071974.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-071974 |
| 2026-02-25 | 16:31 ET | [10-K](/filings/0001193125-26-071776.md) | Annual report, period 2025-12-31 | 0001193125-26-071776 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-071776.md), filed Feb 25, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/18e04b33-0842-4e53-9c60-1c2d4bf57572)

## About the filer

- CIK: 1080014
- Tickers: INVA
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:26 ET. No prices; not investment advice.